Metsera eyes $289M IPO to fund phase 3 weight loss trial… — 바이오 탐색대 — TG.ME

Metsera has set its sights on a hefty $289 million IPO as the next-gen obesity biotech seeks to fund a phase 3 trial of its GLP-1 receptor agonist. | Metsera has set its sights on a hefty $289 million IPO as the next-gen obesity biotech seeks to fund a phase…